Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pds Biotechnology Corp (PDSB)

Pds Biotechnology Corp (PDSB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 302,665
  • Shares Outstanding, K 28,366
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,850 K
  • 60-Month Beta 2.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.66
Trade PDSB with:

Options Overview

Details
  • Implied Volatility 99.48%
  • Historical Volatility 73.16%
  • IV Percentile 21%
  • IV Rank 31.73%
  • IV High 181.94% on 06/07/21
  • IV Low 61.16% on 04/22/21
  • Put/Call Vol Ratio 0.01
  • Today's Volume 1,576
  • Volume Avg (30-Day) 520
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 9,075
  • Open Int (30-Day) 10,739

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.24
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.68 +26.50%
on 07/27/21
11.91 -7.81%
on 07/06/21
-0.93 (-7.81%)
since 07/02/21
3-Month
4.10 +167.80%
on 05/11/21
13.48 -18.55%
on 06/04/21
+5.26 (+91.96%)
since 04/30/21
52-Week
1.84 +496.74%
on 09/04/20
13.48 -18.55%
on 06/04/21
+7.32 (+200.00%)
since 07/31/20

Most Recent Stories

More News
PDS Biotechnology to Present Recent Phase 2 Human Clinical Data and On-Going Oncology Programs at Investor Conferences

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune T-cell activating technology, announced...

PDSB : 10.98 (+2.91%)
PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune T-cell activating technology, will release...

PDSB : 10.98 (+2.91%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of PDS Biotechnology Corporation - PDSB

New York, New York--(Newsfile Corp. - July 12, 2021) - Levi & Korsinsky announces it has commenced an investigation of PDS Biotechnology Corporation (NASDAQ: PDSB) concerning possible breaches of fiduciary...

PDSB : 10.98 (+2.91%)
PDS Biotechnology Joins Russell Microcap(R) Index

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune(R) T-cell activating technology, was...

PDSB : 10.98 (+2.91%)
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating PDS Biotechnology Corporation for Potential Breach of Fiduciary Duty Claims

NEW YORK, NY / ACCESSWIRE / June 28, 2021 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of PDS Biotechnology Corporation .

PDSB : 10.98 (+2.91%)
PDS Biotechnology Corporation Announces Closing of Approximately $52 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing a pipeline of novel cancer therapies based on the Company's proprietary...

PDSB : 10.98 (+2.91%)
PDS Biotech Prices Public Offering of Common Stock

PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune T-cell...

PDSB : 10.98 (+2.91%)
PDS Biotech Announces Proposed Offering of Common Stock

PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune T-cell...

PDSB : 10.98 (+2.91%)
PDS Biotechnology Announces Oncology Research and Development Day

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage cancer immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune T-cell activating technology,...

PDSB : 10.98 (+2.91%)
Company News for Jun 9, 2021

Companies in the news are: MOMO, NAV, ASO, PDSB

NAV : 44.50 (+0.16%)
MOMO : 12.85 (+3.71%)
PDSB : 10.98 (+2.91%)
ASO : 36.76 (-0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company's products are based on the proprietary...

See More

Key Turning Points

3rd Resistance Point 12.29
2nd Resistance Point 11.80
1st Resistance Point 11.39
Last Price 10.98
1st Support Level 10.49
2nd Support Level 10.00
3rd Support Level 9.59

See More

52-Week High 13.48
Last Price 10.98
Fibonacci 61.8% 9.03
Fibonacci 50% 7.66
Fibonacci 38.2% 6.29
52-Week Low 1.84

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar